These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 30118588)

  • 1. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
    Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
    ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dimeric Form of 1,3-Diaminoisoquinoline Derivative Rescued the Mis-splicing of Atp2a1 and Clcn1 Genes in Myotonic Dystrophy Type 1 Mouse Model.
    Matsumoto J; Nakamori M; Okamoto T; Murata A; Dohno C; Nakatani K
    Chemistry; 2020 Nov; 26(63):14305-14309. PubMed ID: 32449537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
    André LM; van Cruchten RTP; Willemse M; Wansink DG
    PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Treatment of Erythromycin and Furamidine Provides Additive and Synergistic Rescue of Mis-Splicing in Myotonic Dystrophy Type 1 Models.
    Jenquin JR; Yang H; Huigens RW; Nakamori M; Berglund JA
    ACS Pharmacol Transl Sci; 2019 Aug; 2(4):247-263. PubMed ID: 31485578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
    Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
    J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
    Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
    PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
    Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
    Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.
    Chen G; Masuda A; Konishi H; Ohkawara B; Ito M; Kinoshita M; Kiyama H; Matsuura T; Ohno K
    Sci Rep; 2016 Apr; 6():25317. PubMed ID: 27126921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
    Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
    RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.
    Carpentier C; Ghanem D; Fernandez-Gomez FJ; Jumeau F; Philippe JV; Freyermuth F; Labudeck A; Eddarkaoui S; Dhaenens CM; Holt I; Behm-Ansmant I; Marmier-Gourrier N; Branlant C; Charlet-Berguerand N; Marie J; Schraen-Maschke S; Buée L; Sergeant N; Caillet-Boudin ML
    Biochim Biophys Acta; 2014 Apr; 1842(4):654-64. PubMed ID: 24440524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
    Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
    Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
    Dansithong W; Paul S; Comai L; Reddy S
    J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy.
    Li M; Zhuang Y; Batra R; Thomas JD; Li M; Nutter CA; Scotti MM; Carter HA; Wang ZJ; Huang XS; Pu CQ; Swanson MS; Xie W
    Proc Natl Acad Sci U S A; 2020 Mar; 117(10):5472-5477. PubMed ID: 32086392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
    Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
    Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
    Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
    Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
    González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
    PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitriol increases MBNL1 expression and alleviates myotonic dystrophy phenotypes in HSA
    Huang K; Wang DD; Hu WB; Zeng WQ; Xu X; Li QX; Bi FF; Yang H; Qiu J
    J Transl Med; 2022 Dec; 20(1):588. PubMed ID: 36510245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
    de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
    Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy.
    Lueck JD; Mankodi A; Swanson MS; Thornton CA; Dirksen RT
    J Gen Physiol; 2007 Jan; 129(1):79-94. PubMed ID: 17158949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
    Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
    J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.